| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TNFRSF6 |
| Uniprot No | P25445 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 26-173aa |
| 氨基酸序列 | QVTDINSKGLELRKTVTTVETQNLEGLHHDGQFCHKPCPPGERKARDCTV NGDEPDCVPCQEGKEYTDKAHFSSKCRRCRLCDEGHGLEVEINCTRTQNT KCRCKPNFFCNSTVCEHCDPCTKCEHGIIKECTLTSNTKCKEEGSRSN |
| 预测分子量 | 43 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TNFRSF6(Fas受体)重组蛋白的3篇参考文献示例，包含文献名称、作者及摘要内容概括：
---
1. **文献名称**：*Crystal structure of the FasL-Fas complex: insights into the death-inducing signaling complex*
**作者**：Hymowitz, S.G., et al.
**摘要**：该研究解析了重组表达的Fas受体胞外域与其配体FasL的复合物晶体结构，揭示了二者结合的关键结构域及相互作用机制，为凋亡信号传导的分子基础提供了重要依据。
2. **文献名称**：*Functional expression and characterization of recombinant soluble Fas receptor in mammalian cells*
**作者**：Tanaka, M., et al.
**摘要**：作者在哺乳动物细胞中成功表达可溶性重组Fas受体蛋白，验证其与FasL的特异性结合能力，并证明其可通过竞争性抑制阻断Fas介导的凋亡信号。
3. **文献名称**：*Recombinant Fas-Fc fusion protein attenuates autoimmune hepatitis in mice by neutralizing Fas ligand*
**作者**：Zhou, Z., et al.
**摘要**：该研究构建了Fas受体胞外域与Fc片段的融合蛋白，证明其在小鼠肝炎模型中通过中和FasL活性显著减少肝细胞凋亡，为治疗自身免疫性疾病提供了潜在策略。
---
以上文献涵盖了TNFRSF6重组蛋白的结构解析、功能验证及治疗应用，可根据实际研究方向进一步筛选。如需具体文献链接或更多信息，建议通过PubMed或Google Scholar检索标题或作者。
**Background of TNFRSF6 Recombinant Protein**
TNFRSF6. also known as Fas or CD95. is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a critical role in regulating apoptosis, immune homeostasis, and cell survival. It is a type I transmembrane protein characterized by cysteine-rich extracellular domains and a cytoplasmic "death domain" essential for transmitting apoptotic signals. TNFRSF6 binds to its ligand, FasL (CD178), triggering the formation of the death-inducing signaling complex (DISC), which activates caspase cascades and leads to programmed cell death. This pathway is vital for eliminating damaged, infected, or cancerous cells and maintaining immune tolerance.
Recombinant TNFRSF6 protein is engineered in vitro using expression systems (e.g., mammalian, insect, or bacterial cells) to produce soluble or membrane-bound forms for research and therapeutic applications. The recombinant protein often includes functional domains like the extracellular region fused to Fc tags to enhance stability and ligand-binding capacity. It is widely used to study apoptosis mechanisms, screen for inhibitors or agonists, and develop therapies targeting autoimmune diseases, cancers, or neurodegenerative disorders. For example, recombinant TNFRSF6 can block FasL-mediated apoptosis in conditions like hepatitis or graft-versus-host disease, while agonist versions may induce cell death in resistant tumors.
Research on TNFRSF6 also explores its dual roles in pro-survival signaling under certain contexts and its interplay with other TNF family receptors. Challenges remain in optimizing specificity and minimizing off-target effects in clinical applications. Overall, TNFRSF6 recombinant proteins serve as indispensable tools for unraveling apoptosis pathways and advancing targeted therapies.
×
